Glycogen synthase kinase-3β and tau genes interact in Alzheimer's disease

Annals of Neurology

Volumn 64, Issue 4, 2008, Pages 446-454

  Kwok, John B J ^a,b,c   Loy, Clement T ^a,b,c   Hamilton, Gillian ^d   Lau, Edmond ^e   Hallupp, Marianne ^a,b   Williams, Julie ^f   Owen, Michael J ^f   Broe, G Anthony ^a,b   Tang, Nelson ^e   Lam, Linda ^g   Powell, John F ^d   Lovestone, Simon ^d   Schofield, Peter R ^a,b,c  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COMPLEMENTARY DNA; GLYCOGEN SYNTHASE KINASE 3BETA; TAU PROTEIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ARTICLE; DNA POLYMORPHISM; DNA TRANSCRIPTION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENICITY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BETA CATENIN; CASE-CONTROL STUDIES; CELL LINE, TRANSFORMED; CEREBELLUM; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TAU PROTEINS; TRANSFECTION;

EID: 55849090651     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21476     Document Type: Article

References (40)

1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-1364.
2. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002;59:1668-1680.
3. Baker M, Graff-Radford D, Wavrant DeVrieze F, et al. No association between Tau haplotype and Alzheimer's disease in population or clinic-based series or in familial disease. Neurosci Lett 2000;285:147-149.
4. Bullido MJ, Aldudo J, Frank A, et al. A polymorphism in the tau gene associated with risk for Alzheimer's disease. Neurosci Lett 2000;278:49-52.
5. Tanahashi H, Asada T, Tabira T. Association between tau polymorphism and male early-onset Alzheimer's disease. Neuroreport 2004;15:175-179.
6. Clark LN, Levy G, Tang MX, et al. The Saitohin 'Q7R' polymorphism and tau haplotype in multi - ethnic Alzheimer disease and Parkinson's disease cohorts. Neurosci Lett 2003;347:17-20.
7. Russ C, Powell JF, Zhao J, et al. The microtubule associated protein Tau gene and Alzheimer's disease - an association study and meta-analysis. Neurosci Lett 2001;314:92-96.
8. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711-715.
9. Myers AJ, Kaleem M, Marlowe L, et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet 2005;14:2399-2404.
10. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005;42:837-846.
11. Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007;25:561-570.
12. Kwok JB, Teber ET, Loy C, et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004;55:329-334.
13. Laws SM, Fredrich P, Diehl-Schmid J, et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol Psychiatry 2007;12:510-517.
14. Caffrey TM, Joachim C, Paracchini S, et al. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet 2006;15:3529-3537.
15. Lovestone S, Reynolds CH, Latimer D, et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994;4:1077-1086.
16. Anderton BH, Dayanadan R, Killick R, Lovestone S. Does dysregulation of Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease. Mol Med Today 2000;6:54-59.
17. Kang DE, Soriano S, Eberhart CG, et al. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation and tumourigenesis. Cell 2002;110:751-762.
18. Zhang Z, Hartman H, Do VM, et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998;395:698-702.
19. Kwok JB, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005;58:829-839.
20. Hamilton G, Proitsi P, Jehu L, et al. Candidate gene association study of insulin signalling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARg as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet 2007;144B:508-516.
21. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
22. Bennett HP, Piguet O, Grayson DA, et al. A six-year study of cognition and spatial function in the demented and non-demented elderly: the Sydney Older Persons Study. Dement Geriatr Cogn Disord 2003;16:181-186.
23. Ma SL, Tang NL, Lam LC, et al. Polymorphisms of the cholesterol 24-hydroxylase (CYP46A1) gene and the risk of Alzheimer's disease in a Chinese population. Int Psychogeriatr 2006;18:37-45.
24. Stanford, PM, Halliday GM, Brooks WS, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau mutations. Brain 2000;123:880-893.
25. Zaykin DV, Westfall PH, Young SS, et al. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002;53:79-91.
26. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989.
27. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
28. Evans E, Fung HC, Steele J, et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett 2004;369:183-185.
29. Mateo I, Infante J, Llorca J, et al. Association between glycogen synthase kinase-3b genetic polymorphism and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21:228-232.
30. Conrad C, Zhu J, Conrad C, et al. Single molecule profiling of tau gene expression in Alzheimer's disease. J Neurochem 2007;103:1228-1236.
31. Wang Y, Wang J, Gao L, et al. Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2-beta. J Biol Chem 2005;280:14230-14239.
32. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, disease and therapeutics. Neurochem Res 2007;32:577-595.
33. Chenn A, Walsh CA. Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in β-catenin over-expressing transgenic mice. Cereb Cortex 2003;13:599-606.
34. Brault V, Moore R, Kutsch S, et al. Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 2001;128:1253-1264.
35. Li H-L, Wang H-H, Liu SJ, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing b-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci USA 2007;104:3591-3596.
36. Levy SF, LeBoeuf AC, Massie MR, et al. Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. J Biol Chem 2005;280:13520-13528.
37. Bertolli-Avella AM, Oostra BA, Heutink P. Chasing genes in Alzheimer's and Parkinson's disease. Hum Genet 2004;114:413-438.
38. Jellinger KA. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J Neural Transm Suppl 2007;72:91-104.
39. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004;19:1043-1049.
40. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003;56:73-82.